CTRI/2012/09/002956已完成未知
A multicentre, balanced, randomized, open label, three-period, two-treatment, three sequences, reference replicate, crossover, bioequivalence study comparing Quetiapine extended release tablets 400 mg (Manufactured by: Pharmathen S.A., Greece) to the reference listed drug Seroquel® Prolong 400 mg tablets (Manufactured by: AstraZeneca UK Limited., United Kingdom) under fasting conditions after multiple dose administration at steady state in adult schizophrenic patients stabilized on Quetiapine 400 mg per day
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 51
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1.Written informed consent for participation in the study by the patient and Patientâ??s Legally Acceptable Representative (LAR)
- •2.Patient has a documented clinical diagnosis of schizophrenia (DSM IV-TR)
- •3.Patient should be on a stable dose of Quetiapine 400 mg per day for at least 14 days prior to screening
- •4.Having a Body Mass Index (BMI) between 18 and 30 (both inclusive), calculated as weight in kg/height in m2
- •5.Able to comply with study procedures in the opinion of the investigator
- •6.In case of female patient the serum pregnancy test at screening visit and urine pregnancy test at day 1 (before dosing) must be negative
- •7.Sexually active women, unless surgically sterile (at least 6 months prior to Study drug administration) or postmenopausal for at least 12 consecutive months, must use an effective method of avoiding pregnancy (including oral, transdermal, or implanted contraceptives [any hormonal method in conjunction with a secondary method], intrauterine device, female condom with spermicide, diaphragm with spermicide, absolute sexual abstinence, use of condom with spermicide by sexual partner or sterile [at least 6 months prior to Study drug administration] sexual partner) for at least 4 weeks prior to study drug administration, during study and up to 30 days after the last dose of study drug
- •8.In case of Male patients: Either partner or patient must use an effective method of avoiding pregnancy for at least 4 weeks prior to study drug administration, during study and up to 30 days after the last dose of study drug
- •(It is investigatorâ??s responsibility to ensure that above points regarding an effective method of avoiding pregnancy are discussed with patient/LAR in detail and patient agreed for this and it is documented in source document. The investigator should ensure that the patient is using an effective method of avoiding pregnancy as per protocol)
排除标准
- •1.Known hypersensitivity or idiosyncratic reaction to Quetiapine and its excipients
- •2.Current or relevant history of serious, severe or unstable psychiatric illness except schizophrenia
- •3.Presence of Postural Hypotension (Defined as systolic blood pressure decrease of at least 20 mm Hg or a diastolic blood pressure decrease of at least 10 mm Hg within three minutes of standing up)
- •4.History of syncope or orthostatic hypotension
- •5.Ingestion of any medication other than listed below at any time in 10 days before the first study drug administration. In any such case Patient selection will be at the discretion of the Principal Investigator / Medical Expert. Following is the list of permissible medications, provided, the patients are on a stable regimen at least 14 days prior to and throughout the study: Alprazolam, Fluoxetin, Imipramine, Haloperidol and Risperidone
- •6.A recent history of alcoholism (less than 2 years) or daily consumption of moderate (180 ml / day) alcohol use, or consumption of alcohol or alcoholic products within 48 hour of receiving study medication or inability to abstain from alcohol during the study
- •7.Smokers who has inability to abstain from smoking during the study
- •8.Donation of blood (1 unit or 350 ml) within 90 days prior to receiving the first dose of study medication or during the study
- •9.A positive hepatitis screen including HBsAg, HCV and HAV IgM antibodies
- •10.Known case of HIV infection
- •11.Supine blood pressure less than 110/70 mmHg or pulse rate less than 60 or more than 100 beats per minute at screening
- •12.Any condition/ Abnormal baseline findings that in the investigatorâ??s judgement might increase the risk to the patient or decrease the chance of obtaining satisfactory data needed to obtain the objective of the study
- •13.The receipt of an investigational product or participation in a drug research study within a period of 30 days prior to the first dose of study medication
- •Note: Elimination half-life of the study drug should be taken into consideration for inclusion of the Patient in the study.
- •14.Psychosis judged to be the direct physiological effect of an abused medication or substance
- •15.Patients with a known intolerance or lack of response to previous treatment with Quetiapine
- •16.Positive testing for the drugs of abuse (amphetamines, barbiturates ,benzodiazepines, cocaine, morphine , marijuana) done by urine drug scan at day 0 (except for Alprazolam which is a permissible medication)
- •17.History of Organic Brain Disorder
- •18.Hospitalisation for an exacerbation of schizophrenia within two months prior to screening and during the screening period
- •19.Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others
- •20.Patients with the following cardiac conditions are excluded:
- •Recent myocardial infarction (12 months)
- •QTc prolongation (screening electrocardiogram with QTc 450 msec for men,QTc 470 msec for women)
- •History of QTc prolongation or using concomitant medications which prolong QTc interval
- •Sustained cardiac arrhythmia or history of sustained cardiac arrhythmia
- •Uncompensated congestive heart failure
- •Complete left bundle branch block
- •First-degree heart block with PR interval 0.22 seconds
研究者
相似试验
尚未招募
不适用
Capecitabine 500mg tablets two treatment will be provided for 4 days to cancer patients and Plasma sample will be collected at multiple time points at different centers in IndiaCTRI/2020/02/023140Hetero Labs Limited
尚未招募
不适用
A clinical study, to Investigate the Safety and bioequivalence study of Capecitabine 500 mg Film Coated Tablets.CTRI/2018/08/015269Onko Ila San ve Tic AS
进行中（未招募）
2 期
Bioequivalence study of Ferric carboxymaltose solution in patients with iron deficiency anemia.CTRI/2024/02/062551DifGen Pharmaceuticals LLC,
已完成
不适用
Two-treatment bioequivalence study of Ferric carboxymaltose solution injection/infusion (50 mg iron/mL) in patients with iron deficiency anemia.CTRI/2022/10/046637Dr. Reddy’s Laboratories Ltd.155
招募中
不适用
Bioequivalence study of Ferric carboxymaltose solution in patients with irondeficiency anemia, for whom oral iron preparations are ineffective or cannot beused, under fasting condition.CTRI/2021/08/035672Dr Reddys Laboratories Ltd